Consistent with previous reports indicating that the RAS/MEK signaling pathway regulates TERT expression [32, 33], treatment of NRAS-mutant melanoma cells with the MEK inhibitor trametinib downregulated TERT mRNA levels (Supplementary Figure 2). This evidence concerns the gene MAP2K7 and melanoma.